The technologies used in histopathology are changing as a consequence of th
e current revolutionary progress in several areas of biology. It is likely
that general cancer management will improve because of the impact of molecu
lar techniques and immunohistochemistry on tumor diagnosis and classificati
on and on the determination of prognosis and response to therapy. Moreover,
as therapies are starting to be modelled after the distinctive molecular c
haracteristics of a specific tumor, the availability of molecular tests to
all patients will become a matter of great importance.